









Markets
/
Stocks
/
nasdaq-itrm
/

Iterum Therapeutics PLC

ITRM

0.670USD

-0.010-1.41%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

28.23MMarket Cap

LossP/E TTM



Iterum Therapeutics PLC

0.670

-0.010-1.41%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

141 / 506

Overall Ranking

249 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+930.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Undervalued

The company’s latest PE is -0.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.58M shares, decreasing 62.32% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 471.90K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.94, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.74

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.84, which is -57.91% below the recent high of -0.35 and 9.32% above the recent low of -0.76.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Iterum Therapeutics PLC is 7.00, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+930.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Iterum Therapeutics PLC

ITRM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.60, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.77 and the support level at 0.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Neutral

RSI(14)

41.811

Neutral

STOCH(KDJ)(9,3,3)

31.589

Neutral

ATR(14)

0.047

Low Volatility

CCI(14)

12.402

Neutral

Williams %R

58.917

Sell

TRIX(12,20)

-0.528

Sell

StochRSI(14)

22.042

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.677

Sell

MA10

0.683

Sell

MA20

0.682

Sell

MA50

0.765

Sell

MA100

0.878

Sell

MA200

1.211

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 3.92%, representing a quarter-over-quarter increase of 2.53%. The largest institutional shareholder is James Simons, holding a total of 471.90K shares, representing 1.06% of shares outstanding, with 24.07% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Renaissance Technologies LLC

Star Investors

240.90K

-45.10%

New Leaf Venture Partners LLC

345.02K

-44.23%

Apollon Financial LLC

250.25K

Dunne (Michael W)

220.00K

OneDigital Investment Advisors LLC

101.00K

Fishman (Corey N)

137.06K

Creative Financial Designs, Inc.

69.95K

+16.77%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.03, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 3.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.